



November 2020

On November 17, 2020 at the close of the 73rd World Health Assembly of the World Health Organisation [WHO], **the resolution to make cervical cancer a rare disease and the official launch of the global elimination strategy to make that happen will occur.**

The International Papillomavirus Society [IPVS] is the learned body of basic scientists, clinical and public health research professionals concerned with human papillomaviruses [HPV] and associated diseases. IPVS facilitates HPV-related research and promotes the translation of evidence-based research results into new clinical applications and improved public health policies. IPVS also serves as the organizational structure for biomedical scientists, physicians and other health care providers engaged in all manner of papillomavirus research.

Cervical cancer is caused by HPV. We have the tools to eliminate cervical cancer: these include safe, effective HPV vaccines that prevent HPV infection which cause diseases such as cervical cancer. Further, we have HPV nucleic acid tests for cervical screening, assays that are more sensitive and precise in predicting and detecting underlying cervical lesions in women. Ablative approaches for treatment of small precancerous lesions is becoming an outstanding approach to manage screening/triage-positive women. Using the tools of vaccination, screening, and timely treatment the development of cervical cancer can be prevented.

Photo: IPVS Board of Directors (from left to right)

Top: E. McClymont, J. Jeronimo (former board member IPVS), E. Chow, S. de Sanjose (past President IPVS), R. Burk (Secretary IPVS), J. Palefsky (Hon. board member IPVS), M. Stanley (President IPVS)

Middle: S. Garland (Vice President IPVS), X. Bosch (former member, past Editor-in-Chief PVR), S. Feldman, T. Malagón, D. Watson-Jones, M. Ozbun (Treasurer IPVS)

Bottom: B. Moscicki, A. Rodriguez, M. Steben, A. Kreimer, N. Egawa, J. Dillner